Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an update.
Mochida Pharmaceutical Co., Ltd. has announced its 25-27 Medium-term Management Plan, aiming to accelerate its growth strategy over the next three years. The plan focuses on strengthening core business profitability, investing in growth sectors like biomaterials and oligonucleotide drugs, and enhancing global expansion efforts. Despite challenges such as rising costs and healthcare policy changes, the company is committed to realizing its Vision for 2031 by enhancing corporate value and supporting growth through its core businesses.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. operates in the pharmaceutical and healthcare industry, focusing on developing innovative drugs and healthcare solutions. The company is known for its pharmaceutical products, healthcare brands, and efforts in biomaterials and regenerative medicine, with a market focus on both domestic and international expansion.
YTD Price Performance: -11.03%
Average Trading Volume: 26,864
Technical Sentiment Signal: Sell
Current Market Cap: Yen105.3B
For detailed information about 4534 stock, go to TipRanks’ Stock Analysis page.